Insights
Insights From Our Experts
Articles
Rewiring Commercialization for Biotech’s New Reality
Biotech companies are facing rapid shifts in how therapies are developed, funded and brought to market. New modalities, compressed timelines and smaller patient populations are creating pressures that traditional commercialization models weren’t designed to support. In…
How Pharma Marketers Can Prepare for the Next Wave of Healthcare AI
Large language model platforms are accelerating their move into healthcare. In early 2026, OpenAI launched ChatGPT Health and OpenAI for Healthcare, while Anthropic introduced Claude for Healthcare with an emphasis on enterprise safety and workflow integration.…
Bringing a Breakthrough Rare Disease Therapy to Market with Rapid Speed for Patients
Launching a first‑in‑class therapy for patients, particularly in rare disease, requires more than strong clinical data. It demands speed, precision and a commercialization strategy built for complexity. Precigen’s recent FDA approval and launch of Papzimeos, the first treatment for adults with recurrent respiratory…
Insights from Frontiers Health 2025: The Future of Commercialization Models
As the global healthcare landscape rapidly evolves, traditional launch playbooks are no longer enough. Emerging technologies, shifting pricing dynamics, and rising commercial expectations are reshaping how therapies and medical devices reach patients. At Frontiers Health 2025,…
Insights from Frontiers Health 2025: How European Biotechs Can Navigate the U.S. Market
For European life sciences companies, breaking into the U.S. market means navigating one of the most competitive and complex healthcare ecosystems in the world. This topic was explored last November at Frontiers Health 2025 in a…
Putting Data Science in the Spotlight
EVERSANA team shares key clinical insights at industry leading events Across the pharmaceutical and life sciences industries, the need for insightful data has never been more important. To truly understand how data can transform patient care, many companies turn to trusted experts. Real-world data becomes meaningful only when interpreted through a clinical, scientific and epidemiological lens. Our Data &…
“Nothing changes if nothing changes.”
Patients deserve quick and easy access to care. That’s why EVERSANA DIRECT goes beyond the “bare minimum” of DTP solutions, delivering a seamless end‑to‑end patient experience—from patient identification through prescription refills. Two-thirds of drug launches fall short of revenue goals, but a new approach is changing…
Navigating A New Era: Reflections on Canada’s Enhanced CDA-AMC Reimbursement Review Process
CDA-AMC’s recent enhancements to the reimbursement review process are reshaping the Canadian HTA landscape. With the first draft recommendations issued under the new framework in late 2025, clear themes are emerging that will influence how Sponsors…
Predicting PICO and Preparing for JCA: Insights from EVERSANA at ISPOR EU
As the EU HTA Regulation moves into implementation, Joint Clinical Assessment (JCA) is reshaping how evidence is planned and delivered across Europe. At ISPOR EU in Glasgow, EVERSANA’s Pamela Vo, VP, HEOR, joined a cross‑stakeholder panel featuring: …
The Combination Crossfire: Is Your Brand Strategy Strong Enough to Align Payers, Prescribers, and Patients?
Navigating Oncology’s Combination Era Combination therapy is now the norm in oncology, with most trials exploring multi-drug regimens. Success depends not just on clinical results, but on how well your brand stands out and performs within…